COMBINAISON PHARMACEUTIQUE COMPRENANT UN AGENT EXTINCTEUR CIP2A UTILISEE DANS LE TRAITEMENT D'UN TROUBLE HYPERPROLIFERATIF AYANT UNE FONCTION P53 AFFECTEE.
The invention is based on a finding that silencing CIP2A (KIAA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject.